Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

USA - engelsk - NLM (National Library of Medicine)

direct rx - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets are indicated for: 1.1 short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (gerd) pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 maintenance of healing of erosive esophagitis pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. 1.3 pathological hypersecretory conditions including zollinger-ellis

USA - engelsk - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4‑ to 8‑ week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age. pediatric patients 1 year to 11 years of age esomeprazole magnesium is indicated for the short-term treatment (8 weeks) for the healing of ee in pediatric patients 1 year to 11 years of age. pediatric patients 1 month to less than 1 year of age esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of ee due to acid-mediated gerd in pediatric patients 1 month to less than 1

USA - engelsk - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. - pantoprazole sodium delayed-release tablets are contraindic

USA - engelsk - NLM (National Library of Medicine)

qpharma inc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. reproduction studies have been performed in rats at oral pant

Israel - engelsk - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 15 mg - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Israel - engelsk - Ministry of Health

raz pharmaceutics ltd, israel - cidofovir as dihydrate - concentrate for solution for infusion - cidofovir as dihydrate 75 mg - cidofovir - cidofovir is indicated for the treatment of cmv retinitis in adults with acquired immunodeficiency syndrome (aids) and without renal dysfunction. it should be used only when other medicinal products are considered unsuitable.